Volume 19 (2021): Issue 3.5 (Mar 2021): Abstracts from the NCCN 2021 Virtual Annual Conference

in Journal of the National Comprehensive Cancer Network
Online ISSN:
1540-1413
Print ISSN:
1540-1405
Cover Journal of the National Comprehensive Cancer Network
Young Investigator Awards
Best Practices in Implementation and Use of Clinical Practice Guidelines
BPI21-003: Analysis of NAPBC Accreditation Data From a Multi-Disciplinary Accredited Unit in JHB SA Shows That Tumour Biology Not Stage Dictates Treatment Choice With an Increasing Use of Neo-Adjuvant Chemotherapy (NACT)
BPI21-004: A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States
BPI21-005: Barriers and Facilitators for Clinical Trial Enrollment: A Qualitative Study of the Perspectives of Healthcare Providers
BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients
BPI21-007: Physician Adherence to Treatment Guidelines Based on Priority Groups for Breast Cancer Patients During the COVID-19 Pandemic
BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer
BPI21-009: Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid: A Systematic Review
Bioinformatics/Information Technology Sciences
Clinical Oncology
CLO21-012: Isolation and Characterization of Circulating Tumor DNA to Monitor Acute Lymphoblastic Leukemia
CLO21-013: Atrial Fibrillation With Ibrutinib Therapy: Potential Pharmacologic Interactors in a Single-Institution Retrospective Study
CLO21-014: Impact of Late Dosing on Testosterone Suppression With Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere – an Analysis of US Clinical Data
CLO21-015: A Unique Case of Duodenal Extraosseous Ewing Sarcoma in an Elderly Filipina
CLO21-016: Incidence, Risk Factors, and Prognostic Implications of Peri-Transplant Orthostatic Hypotension in Patients With Multiple Myeloma
CLO21-017: Hospitalization and Supportive Care Measure (SCM) Utilization in Patients With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC) in EMBRACA: Results From an Extended Follow-up Post-hoc Analysis
CLO21-018: Clinical Characteristics of Breast Cancer Patients Treated With Trastuzumab-anns, a Trastuzumab Biosimilar, in a Real-World Setting
CLO21-019: Association Between Oncotype Dx Breast Recurrence Score® and Estrogen and Progesterone Receptor Status
CLO21-020: Pembrolizumab in Metastatic Non-Squamous and Squamous Non-Small Cell Lung Cancer (NSCLC): Real World Data Results
CLO21-021: Impact on Survival of the Number of Lymph Nodes Resected in Patients With Esophageal Cancer Following Neo-Adjuvant Therapy
CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review
CLO21-023: Antiviral Therapy Improves Hepatocellular Cancer Survival
CLO21-024: Serial Circulating Tumor DNA Analysis for Treatment Monitoring in an Inflammatory Triple-Negative Breast Cancer Patient
CLO21-025: Benefit of Deep Inspiratory Breath Hold for Right Breast Cancer When Regional Lymph Nodes Are Irradiated
CLO21-026: Comparative Analysis of Pembrolizumab And Nivolumab Related Immune Toxicity
CLO21-027: Defining Optimal Lymph Node Dissection and Clinical Impact of Number of Harvested Lymph Nodes During Esophageal Resection for Early Stage Esophageal Cancer
CLO21-028: Clinical Outcomes for Advanced Hepatocellular Carcinoma Patients Treated With Systemic Agents in Real-World Practice
CLO21-029: Impact of Comorbidity Patterns on the Outcomes of Older Patients With Diffuse Large B- Cell Lymphoma
CLO21-030: Does the TP53 Mutation Worsen Prognosis in Carriers of BRCA1/2 Deficiency With Grade 3 Endometrioid Endometrial Carcinoma?
Correlative/Genomic
Epidemiology/Risks/Prevention
EPR21-032: Need for Smoking Cessation Counseling in Patients With Malignancy
EPR21-033: Testicular Cancer Trends and Disparities in the United States
EPR21-034: Epidemiology of Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Patients by Line of Therapy in the United States (US) and Europe (EU)
EPR21-035: Immune Checkpoint Inhibitor-Related Hemophagocytic Lymphohistiocytosis: A Food and Drug Association Adverse Event Reporting System (FAERS) Analysis
EPR21-036: Osteoporosis Screening and Referral is Underutilized in a High Risk Population of Patients With Gynecologic Malignancies
EPR21-037: Prevalence of Low HER2 Expression Among HER2 Negative Metastatic Breast Cancer Patients in U.S: Multi-Site, Retrospective Chart Review Study
EPR21-038: Characterizing Surgical Oncology Cases During the COVID-19 Pandemic
EPR21-039: Socioeconomic Disparities in Receipt of Care in Lung Cancer
EPR21-040: Prescribing Patterns at the End of Life in Lung Cancer
Outcomes and Health Services Research
HSR21-041: Impact of Cardiac Comorbidities on Outcomes After Treatment for Locally Advanced Esophageal Cancer: An Institutional Experience
HSR21-042: Disparities in Care Among Adolescent and Young Adult Cancer Patients Based on Residential Metro Versus Non-Metro Categorization and Distance From Cancer Treatment Site
HSR21-043: Racial and Ethnic Disparities in Surgery for Kidney Cancer: A SEER Analysis, 2007-2014
HSR21-044: Tumors of Distal Biliary Tract: Demographics and Survival Analysis
HSR21-045: Genetic Counselor Coverage Disparities & Inequities in Access to Precision Cancer Care
HSR21-046: A Novel Oncology Telepharmacy Service With Improved Medication Access for a More Seamless Patient Experience: A Randomized Controlled Trial
HSR21-047: Tumor Lysis Syndrome Risk Analysis in a US Community Oncology Setting: A Retrospective Observational Study in Integra Connect Network
HSR21-048: Efficacy of Varenicline in Light and Intermittent Smokers
HSR21-049: Fragmentation of Care in the Multidisciplinary Management of Pancreatic Cancer: Luxury or Liability?
HSR21-050: Access to Gastroenterology and Internal Medicine Physicians is Associated With Improved Outcomes in Colorectal Cancer: A Nation-Wide Analysis
HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting
HSR21-052: Prediction of Readmission and Complications After Pituitary Adenoma Resection via the National Surgical Quality Improvement Program (NSQIP) Database
HSR21-053: Identifying Clinically Important Changes of Grip Strength Over Time in Patients With Hematological Malignancy
HSR21-054: Functional Changes in Acute Care for Patients with Hematological Malignancies
HSR21-055: Treatment Patterns and Healthcare Resource Utilization in First-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma in Asian and Western Countries
HSR21-056: The Effect of a Christian-Based Support Group on the Emotional Health of Cancer Survivors and Caregivers
HSR21-057: Cost-Effectiveness of Cemiplimab vs Pembrolizumab for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) and Programmed Death-Ligand 1 (PD-L1) Expression ≥50% in the US
HSR21-058: Advance Care Planning for Patients Diagnosed With Metastatic Breast Cancer in the U.S.
HSR21-059: Telehealth is Here—Are Patients Ready for It? An Analysis of Technological Knowledge in Cancer Patients
HSR21-060: Real-World Treatment Patterns After Trastuzumab-Based Regimen in Patients With HER2-Positive Metastatic Gastric Cancer in the United States
HSR21-061: Frequency of Oncologists (ONC) Office Visit and Caregiver Burden With Poly(ADP-ribose) Polymerase Inhibitor (PARPi) Versus Chemotherapy (CTX) Among Adult Patients (pts) With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC): Results From a Multi-Country Real-World (RW) Study
HSR21-062: Real-World Study of BRCA1/2 Mutation (BRCA1/2mut) Testing Among Adult Patients (pts) With HER2− Advanced Breast Cancer (ABC) in the US
HSR21-063: Treatment Patterns Among Patients With EGFR Mutated Metastatic NSCLC Who Have Discontinued EGFR-TKI and Platinum-Based Chemotherapy Regimens
HSR21-064: The Effectiveness of Psychological Intervention on Reducing Distress in Patients With Prostate Cancer: A Literature Meta-Analysis
HSR21-065: Oncologists’ Perceptions and Utilization of Therapeutic Oncology Biosimilars in the U.S.
HSR21-066: A Retrospective Analysis of Tumor Recurrence of Locally Advanced Cervical Cancer in a Tertiary Government Hospital
HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling
HSR21-068: Predicting Preventable Emergency Department Visits and Admissions After Chemotherapy
HSR21-069: Factors Associated With Time to Treatment With an EGFR-TKI Among Patients With Non-Squamous Metastatic Non-Small Cell Lung Cancer: A SEER-Medicare Analysis
HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)
HSR21-071: Healthcare Utilization Between Blood and Solid Cancer Survivors and Implications for Financial Toxicity: Results From the National Health Interview Survey, 2009-2018
HSR21-072: Neoadjuvant Chemotherapy in Breast Cancer Care: Does Equal Access Mitigate Racial Disparities?
HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018
HSR21-074: Respiratory Viral Infections Continue to be an Unresolved Problem in the Care of Immunocompromised Transplant Patients
HSR21-075: CancerSupportSource®-Caregiver: Psychometric Properties of 2-Item Depression and Anxiety Risk Screening Measures for Informal Cancer Caregivers
HSR21-076: Valued Outcomes in the Cancer Experience (VOICE™): Developing and Validating a Measure of Patient Experience
Quality Improvement
QIM21-077: Expansion and Sustainability of Tobacco Treatment in Cancer Care at Stanford Health Care
QIM21-078: Women Representation in Clinical Practice Guidelines (CPGs) Among Major Cancer Organizations
QIM21-079: Improving the Process to Timely Administration of Inpatient Chemotherapy
QIM21-080: Patterns of Patient Portal Use in Patients With Cancer Who Utilized the Portal Frequently: Results From the UWCCC Survivorship Program
QIM21-081: Shared Medical Appointments for Cancer Survivors: A Feist Weiller Cancer Center Pilot Study
QIM21-082: Germline Testing in Pancreatic Adenocarcinoma: A Single Academic Center Experience
QIM21-083: Quantitative Evaluation of Methods Designed to Improve the Accuracy and Quality of Multi-Gene Panel Testing for Hereditary Cancer
QIM21-084: Perceived Needs and Patient Satisfaction of Psychosocial Distress Screening and Management in Inpatient Hematology Oncology Specialty Care
QIM21-085: Use of a Surgical Stepdown Protocol for Cost Reduction after Transsphenoidal Pituitary Adenoma Resection
QIM21-086: Implementation of Depression Screening With the Patient Health Questionnaire-9 (PHQ-9) at a Radiation Oncology Department
QIM21-087: Genetic Testing of Newly Diagnosed Ovarian Cancer Patients in a Regional Cancer Center in Appalachia
QIM21-088: Recommendations for Improvement of Turnaround Time in Rectal Adenocarcinoma Specimens: A Retrospective Study of 53 Cases
QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events
QIM21-091: Patterns of Health Portal Usage Among Patients With Cancer During the Year of Diagnosis: Results From the UWCCC Survivorship Program
QIM21-092: Implementing a Mobility Scale to Increase Postoperative Mobility Levels
QIM21-093: Guideline and Standard Development for Medically Integrated Dispensing Pharmacies for Oral Anticancer Medication: ASCO/NCODA Standards
QIM21-094: Strategies to Improve Neuropsychological (NP) Care in Pediatric Oncology: Quality Improvement Findings
QIM21-095: Barriers to Timely Referral of Patients with Terminal Cancer to Hospice Care: A Retrospective Review
  • Collapse
  • Expand